Propylene Glycol

Propylene Glycol

SCHEMBL3664673

CC(O)CO.O.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4245299-A2 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate Astrazeneca AB (SE) 2023-09-20 EP disclosed
EP-2508188-B1 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate ASTRAZENECA AB (SE) 2023-05-10 EP disclosed
WO-2022067724-A1 SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF 北京睿创康泰医药研究院有限公司 2022-04-07 WO disclosed
EP-2139494-B1 PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE ASTRAZENECA AB (SE) 2020-03-11 EP disclosed
US-9198925-B2 Pharmaceutical formulations containing an SGLT2 inhibitor ASTRAZENECA AB (SE) 2015-12-01 US disclosed
US-20140243262-A1 PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR ASTRAZENECA AB (SE) 2014-08-28 US disclosed
US-8361972-B2 Pharmaceutical formulations containing an SGLT2 inhibitor BRISTOL MYERS-SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120263786-A1 Pharmaceutical Formulations Containing an SGLT2 Inhibitor BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-18 US disclosed
EP-2508188-A1 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate Bristol-Myers Squibb Company (US) 2012-10-10 EP disclosed
US-8221786-B2 Pharmaceutical formulations containing an SGLT2 inhibitor BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 US disclosed
US-7851502-B2 Dapagliflozin propylene glycol hydrate; diabetes; immediate release; sodium dependent glucose transporter (SGLT2) inhibitor BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-14 US disclosed
EP-2139494-A1 PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE Bristol-Myers Squibb Company (US) 2010-01-06 EP disclosed
WO-2008116179-A1 PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE BRISTOL-MYERS SQUIBB (US) 2008-09-25 WO disclosed
US-20080234366-A1 Dapagliflozin propylene glycol hydrate; diabetes; immediate release; sodium dependent glucose transporter (SGLT2) inhibitor BRISTOL-MYERS SQUIBB (US) 2008-09-25 US disclosed
EP-1251833-A1 GELLAN GUM DIPPED PRODUCTS MONSANTO COMPANY, Pharmaceutical Ingredients (US) 2002-10-30 EP disclosed
WO-2001056550-A1 GELLAN GUM DIPPED PRODUCTS MONSANTO COMPANY (US) 2001-08-09 WO disclosed